Design Therapeutics Inc DSGN.OQ DSGN.O is expected to show no change in quarterly revenue when it reports results on March 9 (estimated) for the period ending December 31 2025
LSEG's mean analyst estimate for Design Therapeutics Inc is for a loss of 35 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Design Therapeutics Inc is $13.00, about 28.8% above its last closing price of $10.09
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.35 | -0.34 | -0.30 | Beat | 12.6 |
Jun. 30 2025 | -0.34 | -0.33 | -0.34 | Missed | -3 |
Mar. 31 2025 | -0.29 | -0.28 | -0.31 | Missed | -10.7 |
Dec. 31 2024 | -0.27 | -0.24 | Beat | 10 | |
Sep. 30 2024 | -0.22 | -0.24 | -0.23 | Beat | 5.5 |
Jun. 30 2024 | -0.21 | -0.23 | -0.21 | Beat | 10 |
Mar. 31 2024 | -0.25 | -0.26 | -0.20 | Beat | 24.1 |
Dec. 31 2023 | -0.31 | -0.21 | Beat | 32.2 |
This summary was machine generated March 6 at 12:48 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)